Develop a Compact RNA Base Editor by Fusing ADAR with Engineered EcCas6e

分享:

简介:

  • 作者: Xing Wang, Renxia Zhang, Dong Yang, Guoling Li, Zhanqing Fan, Hongting Du, Zikang Wang, Yuanhua Liu, Jiajia Lin, Xiaoqing Wu, Linyu Shi, Hui Yang, Yingsi Zhou
  • 杂志: Advanced Science
  • Doi: https://www.doi.org/10.1002/advs.202206813
  • 出版日期: 2023 Apr 25

论文中使用的产品/服务

Quotation shows PackGene:AAV9 Production and Delivery to DMDQ1392X Mice: AAVs were produced by PackGene Biotech, and applied iodixanol density gradient centrifugation for purification.

Research Field:RNA editing

AAV Serotype:AAV9

Animal or cell line strain:8-week-old male DMDQ1392X mice

询价

摘要

Catalytically inactive CRISPR-Cas13 (dCas13)-based base editors can achieve the conversion of adenine-to-inosine (A-to-I) or cytidine-to-uridine (C-to-U) at the RNA level, however, the large size of dCas13 protein limits its in vivo applications. Here, a compact and efficient RNA base editor (ceRBE) is reported with high in vivo editing efficiency. The larger dCas13 protein is replaced with a 199-amino acid EcCas6e protein, derived from the Class 1 CRISPR family involved in pre-crRNA processing, and conducted optimization for toxicity and editing efficiency. The ceRBE efficiently achieves both A-to-I and C-to-U base editing with low transcriptome off-target in HEK293T cells. The efficient repair of the DMD Q1392X mutation (68.3±10.1%) is also demonstrated in a humanized mouse model of Duchenne muscular dystrophy (DMD) after AAV delivery, achieving restoration of expression for gene products. The study supports that the compact and efficient ceRBE has great potential for treating genetic diseases.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载